Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment

BACKGROUND: PLK1 overexpression is oncogenic and is associated with poor prognosis in various cancers. However, the current PLK1 inhibitors have achieved limited clinical successes. On the other hand, although immunotherapies are demonstrating efficacy in treating many refractory cancers, a substant...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengyuan, Liu, Zhixian, Wang, Xiaosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304487/
https://www.ncbi.nlm.nih.gov/pubmed/30631355
http://dx.doi.org/10.1155/2018/3979527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304487/
https://www.ncbi.nlm.nih.gov/pubmed/30631355
http://dx.doi.org/10.1155/2018/3979527

Ejemplares similares